Apoptosis News and Research

RSS

Apoptosis is programmed cell death, the body's normal method of disposing of damaged, unwanted, or unneeded cells.

Mechanisms of recurrent bacteria AOM in children under scrutiny

The immune response in young children with bacterial acute otitis media differs between individuals who are prone to such infection and those who are not, US researchers have shown.

16 Jun 2014

Study: The brain controls cellular process that leads to glaucoma

Findings from a new study published in Translational Vision Science & Technology show the brain, not the eye, controls the cellular process that leads to glaucoma. The results may help develop treatments for one of the world's leading causes of irreversible blindness, as well as contribute to the development of future therapies for preserving brain function in other age-related disorders like Alzheimer's.

6 Jun 2014

FDA approves Can-Fite's study protocol for CF102 Phase II clinical trial for advanced liver cancer

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that the U.S. FDA has agreed with the Company's study protocol for its Phase II clinical trial of CF102 for the treatment of advanced liver cancer.

2 Jun 2014

Fibrogen reports FG-3019 Phase 2 study results for treatment of pancreatic cancer

FibroGen, Inc. today announced results from a Phase 2 open-label study of FG-3019, an investigational anti-fibrotic antibody, in combination with gemcitabine and erlotinib for the treatment of patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC).

31 May 2014

Researchers resolve long-standing mystery of enzyme's role in cell survival

St. Jude Children's Research Hospital solves mystery of enzyme's role in cell survival, offering clues of how immune system fights infection and possible strategies to treat problems ranging from heart attack to cancer.

23 May 2014

NCCN receives $2M grant to evaluate effectiveness of volasertib in treatment of hematologic malignancies

The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) has been awarded a $2-million grant from Boehringer Ingelheim Pharmaceuticals, Inc.

23 May 2014

Genprex initiates Phase II clinical trial of Oncoprex for late-stage lung cancer patients

Genprex, Inc. announced today that it has enrolled the first patient in a clinical trial evaluating its lead product candidate Oncoprex in combination with erlotinib (Tarceva) for late-stage lung cancer patients.

21 May 2014

St. Jude analysis reveals how protein p53 triggers cancer cells to commit suicide

St. Jude Children's Research Hospital scientists have mapped the structural details of how p53 attaches to its regulatory protein, called BCL-xL, in the cell.

16 May 2014

Pro-urokinase promotes angiogenesis but does not reduce neuronal apoptosis in infarcted cerebral tissue

Among the drugs used for acute ischemic stroke, recombinant tissue plasminogen activator is widely accepted internationally. In China, urokinase has been widely used for thrombolysis after acute ischemic stroke.

13 May 2014

Melbourne researchers find link between necroptosis and inflammatory disease

A team of Melbourne researchers has shown a recently discovered type of cell death called necroptosis could be the underlying cause of inflammatory disease.

13 May 2014

Study of rare childhood neurodegenerative diseases identifies new source of DNA damage

St. Jude Children's Research Hospital scientists studying two rare, inherited childhood neurodegenerative disorders have identified a new, possibly common source of DNA damage that may play a role in other neurodegenerative diseases, cancer and aging.

12 May 2014

McGill research finds unexpected link between cell suicide and longevity

What is the secret to aging more slowly and living longer? Not antioxidants, apparently.

9 May 2014

TAG-1 induces apoptosis-related gene expression without triggering apoptosis in glioma cells

A recent study reported by Haigang Chang and co-workers from the First Affiliated Hospital of Xinxiang Medical University in China verified the effects of transient axonal glycoprotein-1 (TAG-1) on cell viability and p53, epidermal growth factor receptor (EGFR), and amyloid precursor protein (APP) intracellular C-terminal domain (AICD) expression in U251 glioma cells.

8 May 2014

RAAV/ABAD-DP-6His generates fusion peptide that protects PC12 cells from oxidative stress injury

The effects of Amyloid beta (Aβ)-Aβ-binding alcohol dehydrogenase (ABAD) may exacerbate Alzheimer's disease pathology.

8 May 2014

New study explores how bacterial pathogen Yersinia tries to outsmart immune cell responses

A new study led by scientists at the University of Pennsylvania School of Veterinary Medicine has painted a clearer picture of the delicate arms race between the human immune system and a pathogen that seeks to infect and kill human cells.

6 May 2014

Can-Fite BioPharma submits study protocol to FDA for CF102 Phase II trial for advanced liver cancer

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that it has submitted a study protocol to the U.S. Food and Drug Administration for its Phase II clinical trial of CF102 for the treatment of advanced liver cancer.

29 Apr 2014

AGA Research Foundation announces 2014 AGA Research Scholars

The American Gastroenterological Association Research Foundation is pleased to announce the 2014 AGA Research Scholars. The AGA Research Scholar Awards program, launched in 1984, enables young investigators to develop independent and productive research careers in digestive diseases. This year, the AGA Research Scholar Awards fund an additional year allowing for three consecutive years of funding.

25 Apr 2014

Researchers uncover Noxa and MCL-1 as potential targets for small cell lung cancers therapies

Approximately 15 percent of all lung cancers are small cell lung cancers (SCLC), which grow rapidly and often develop resistance to chemotherapy. However, researchers at Virginia Commonwealth University Massey Cancer Center have revealed new insights into the mechanisms leading to this resistance that may lead to improved therapies.

25 Apr 2014

Can-Fite BioPharma signs agreement with Smart Assays to develop A3AR predictive biomarker kit

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today it has signed an agreement with Smart Assays to develop a commercial biomarker blood test kit for the A3 adenosine receptor (A3AR).

21 Apr 2014

FDA and EC grant Orphan Drug Designation to Boehringer’s volasertib for acute myeloid leukemia

Boehringer Ingelheim Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) and European Commission (EC) have granted Orphan Drug Designation to volasertib for acute myeloid leukemia (AML).

21 Apr 2014

Apoptosis News and Research

Mechanisms of recurrent bacteria AOM in children under scrutiny

Study: The brain controls cellular process that leads to glaucoma

FDA approves Can-Fite's study protocol for CF102 Phase II clinical trial for advanced liver cancer

Fibrogen reports FG-3019 Phase 2 study results for treatment of pancreatic cancer

Researchers resolve long-standing mystery of enzyme's role in cell survival

NCCN receives $2M grant to evaluate effectiveness of volasertib in treatment of hematologic malignancies

Genprex initiates Phase II clinical trial of Oncoprex for late-stage lung cancer patients

St. Jude analysis reveals how protein p53 triggers cancer cells to commit suicide

Pro-urokinase promotes angiogenesis but does not reduce neuronal apoptosis in infarcted cerebral tissue

Melbourne researchers find link between necroptosis and inflammatory disease

Study of rare childhood neurodegenerative diseases identifies new source of DNA damage

McGill research finds unexpected link between cell suicide and longevity

TAG-1 induces apoptosis-related gene expression without triggering apoptosis in glioma cells

RAAV/ABAD-DP-6His generates fusion peptide that protects PC12 cells from oxidative stress injury

New study explores how bacterial pathogen Yersinia tries to outsmart immune cell responses

Can-Fite BioPharma submits study protocol to FDA for CF102 Phase II trial for advanced liver cancer

AGA Research Foundation announces 2014 AGA Research Scholars

Researchers uncover Noxa and MCL-1 as potential targets for small cell lung cancers therapies

Can-Fite BioPharma signs agreement with Smart Assays to develop A3AR predictive biomarker kit

FDA and EC grant Orphan Drug Designation to Boehringer’s volasertib for acute myeloid leukemia

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News